Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Top 100 Creative Companies

- PMLiVE

Merck and Orna agree on deal worth $3.5bn for RNA technology

The companies will work together to develop proprietary circular RNA technology

- PMLiVE

AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer

Prostate cancer is the second most common cancer in male patients in the US, projected to cause around 35,000 deaths in 2022

- PMLiVE

bluebird bio’s beta-thalassaemia gene therapy receives FDA approval

Patients with the most severe form of the blood disorder develop life-threatening anaemia and have to receive regular blood transfusions

- PMLiVE

GSK’s application for momelotinib in myelofibrosis with anaemia accepted by FDA

40% of myelofibrosis patients are already anaemic at the time of diagnosis and nearly all patients are estimated to develop anaemia eventually

- PMLiVE

Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics

The deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib

- PMLiVE

Hanover Health appoints James Mole as a director

Mole previously served as deputy director of communications at NHS England

- PMLiVE

Are we the masters or servants of omnichannel engagement?

I think very few people will have failed to notice that our industry is currently in somewhat of a turmoil, as each company and team look at how they can...

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvement for breast cancer patients

The phase 3 trial compared Enhertu against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer

- PMLiVE

JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign

The programme was expanded in response to the Omicron variant to include everyone aged 50 and over

- PMLiVE

Gilead Sciences announce positive results for Trodelvy in breast cancer patients

HR+/HER2- breast cancer accounts for around 70% of all new cases, or nearly 400,000 diagnoses worldwide each year

- PMLiVE

UK government to launch national mission to tackle dementia

One million people are predicted to be living with dementia by 2025

- PMLiVE

WHO publishes first position paper on optimising brain health

It is estimated that one in three people will develop a neurological disorder at some point in their life, making neurological disorders the leading cause of disability

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links